Companies: 10,795·Total market cap: $144.5T
Cantabio Pharmaceuticals, Inc.

Cantabio Pharmaceuticals, Inc.

CTBOOTCHealthcare● Active
$1.01
+$0.00(+0.00%)
Market Cap$22769
P/E Ratio
52W High$1.01
52W Low$1.01

Cantabio Pharmaceuticals, Inc. (CTBO) Revenue

Annual & quarterly revenue history · segment & region breakdown

CTBO · revenue · updated Jun 9, 2026

Core revenue metrics

Cantabio Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
15 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Cantabio Pharmaceuticals, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
CTBO revenue by year · CTBO revenue history · CTBO annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Cantabio Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Cantabio Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Cantabio Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

CTBO revenue · 4 questions

CTBO's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

CTBO revenueCTBO annual revenuewhat is CTBO revenueCTBO TTM revenue

Source: FMP · Cantabio Pharmaceuticals, Inc. SEC filings · GAAP · Cantabio Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026